Cochrane · systematic review · CD012893
Certolizumab pegol for induction of remission in Crohn's disease
Yamazaki, H, So, R, Matsuoka, K, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Certolizumab pegol compared to placebo for induction of remission in Crohn's disease
Population: Patients with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Certolizumab pegol vs placebo | RR 1.36 [1.11, 1.66] | 4 studies · 1485 participants | Moderate Downgraded: risk of bias, imprecision |
Clinical response Certolizumab pegol vs placebo | RR 1.29 [1.09, 1.53] | 4 studies · 1485 participants | Moderate Downgraded: risk of bias, imprecision |
Serious adverse events Certolizumab pegol vs placebo | RR 1.35 [0.93, 1.97] | 4 studies · 1485 participants | Moderate Downgraded: risk of bias, imprecision |